The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

N.A. Avxentyev

Research Financial Institute of the Ministry of Finance of the Russian Federation;
Russian Academy of National Economy and Public Administration under the President of the Russian Federation;
Health and Market Access Consulting LLC

A.S. Makarov

Health and Market Access Consulting LLC

M.Yu. Frolov

Volgograd State Medical University;
Volgograd Medical Scientific Center

Cost-effectiveness analysis of talazoparib and olaparib for breast cancer in adults

Authors:

N.A. Avxentyev, A.S. Makarov, M.Yu. Frolov

More about the authors

Views: 1172

Downloaded: 2


To cite this article:

Avxentyev NA, Makarov AS, Frolov MYu. Cost-effectiveness analysis of talazoparib and olaparib for breast cancer in adults. Medical Technologies. Assessment and Choice. 2023;(1):89‑98. (In Russ.)
https://doi.org/10.17116/medtech20234501189

Recommended articles:
Quality of life in breast cancer patients after imme­diate two-stage reco­nstruction. Plastic Surgery and Aesthetic Medi­cine. 2023;(2):47-53
Comprehensive analysis of the effi­cacy of personalized reha­bilitation programs in patients with breast cancer. Problems of Balneology, Physiotherapy and Exercise Therapy. 2023;(2):31-38
Cardiac moni­toring of neoadjuvant chemotherapy in a patient with breast cancer. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(3):309-312

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.